Neurosom closes oversubscribed bridge round — FDA cleared NEAT AI, NIH NIA Phase II grant, targeting H1 2026 Seed round
Summary
Neurosom closed an oversubscribed bridge round January 6, 2026 led by Portland Seed Fund's Intrepid Oregon Fund with Loomis Family Trust, OEN Angel Syndicate, and ONAMI. Key milestones driving investor confidence: FDA clearance of NEAT AI software for Sleep WISP therapy system; NIH National Institute of Aging Phase II funding for MCI clinical trial; 2025 Oregon OEN Angel Oregon Life & BioScience Award. Targeting H1 2026 Seed round.
Why it matters
Dual NIH NIA Phase II and FDA clearance milestones for a pre-seed Oregon company are extraordinary achievements that justify an oversubscribed bridge round. The NIH NIA specifically funds promising Alzheimer's prevention research — their award signals the scientific peer review community endorses Neurosom's glymphatic clearance through sleep enhancement hypothesis as worthy of clinical investigation at scale.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial